Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers reviewed current treatments for trichotillomania and found that psychotherapy, particularly cognitive-behavioral therapy like habit reversal training, is most effective, with some medications helping to alleviate symptoms, though further study is needed on their use.

This study observed that different alkaline buffers had a significant impact on the volume of liquid consumed by fall armyworm larvae, emphasizing the importance of measuring imbibed volumes to reduce dose errors in bioassays.

This narrative review reported that direct-to-consumer teledermatology improves access to care, adherence, and patient satisfaction for treating male androgenetic alopecia, but may lead to higher drug costs.

This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.

This review discusses recent advancements in behavioral and pharmacological treatments for trichotillomania but does not report new clinical results, emphasizing the need for rigorous future research.

This review discusses the guidelines for using and monitoring mood stabilizers in bipolar disorders, highlighting that only a minority of patients receive guideline-adherent monitoring.

This article discusses various limitations of direct-to-consumer teledermatology platforms, highlighting concerns regarding ethical issues, financial conflicts of interest, and challenges in providing comprehensive patient care compared to traditional in-person consultations.

In this study, dutasteride 1 mg daily reduced heavy drinking days and drinks per week among treatment-seeking men, particularly benefiting those with high baseline drinking to cope motives.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

At Week-104 of the BRAVE-AA2 trial, this study found that 90.2% of severe alopecia areata patients who continued on baricitinib 4mg maintained hair regrowth, whereas 45.2% of those who reduced their dosage to 2mg experienced a loss of treatment benefit.

This study found that one session of intradermal botulinum toxin type A injection decreased scalp sebum secretion and perception of greasiness more effectively than saline for up to 3 months.

This study identifies a specific subtype of Telogen Effluvium associated with scalp dysesthesia, such as itch or burning, in the absence of any inflammatory scalp disorder or medication association.

This commentary discusses ethical concerns with direct-to-consumer teledermatology services, highlighting potential conflicts of interest and issues with care quality.

This study found that administering botulinum toxin A via Flex-PADs to mouse footpads inhibited sweating similarly to traditional injections, suggesting a promising patient-friendly delivery method for hyperhidrosis treatment.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This study found that oral administration of Terminalia bellirica enhanced hair growth in testosterone-suppressed conditions in both human cell and mouse models, outperforming finasteride, a current commercial hair loss treatment.

This review discusses the clinical features of trichotillomania and the challenges in its diagnosis and treatment, reporting no new clinical findings while highlighting the need for specialized therapy and better therapeutic options.

This paper discusses a structure-based analysis to find new BRD4 inhibitors, identifying finasteride and amentoflavone as promising candidates for BET inhibition.

This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.

In this study, researchers reported that individuals from iodine-deficient regions have an increased risk of developing hypothyroidism from MDR-TB treatment regimens containing PAS and/or Prothionamide.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

Finasteride significantly reduced tics and obsessive-compulsive symptoms in Tourette syndrome patients.

This report discusses the challenges of interpreting bone mineral density in transgender individuals undergoing hormone therapy and highlights the lack of guidelines for assessing fracture risk or BMD results in this population.

This article reviews the genetic and phenotypic characteristics of Trichothiodystrophy and discusses the associated DNA repair defects, but does not report new clinical findings.

This review discusses the transformative potential of direct-to-consumer (DTC) hair regrowth solutions and reports no clinical results; it emphasizes innovation, personalization, and trust in reshaping the industry.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

This case report documents a rare instance of body-focused repetitive behavior in a 37-year-old male physician who compulsively pulled hair from his thighs due to exam stress, highlighting the variability in presentation and demographics of such disorders and the potential for psychiatric comorbidity.